Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors

Journal of Virology

Volumn 76, Issue 21, 2002, Pages 10951-10959

  Feng, Wen hai ^a   Westphal, Eva ^a   Mauser, Amy ^a   Raab Traub, Nancy ^a   Gulley, Margaret L ^a   Busson, Pierre ^a   Kenney, Shannon C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN BRLF1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; TUMOR CELL; VIRUS GENOME; VIRUS INFECTION;

ADENOVIRUSES, HUMAN; ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE; DISEASE MODELS, ANIMAL; DNA REPLICATION; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NECROSIS; NEOPLASMS, EXPERIMENTAL; STOMACH NEOPLASMS; TRANS-ACTIVATORS; VIRAL PROTEINS;

EID: 0036838606     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.21.10951-10959.2002     Document Type: Article

References (57)

1. Adamson, A. L., D. Darr, E. Holley-Guthrie, R. A. Johnson, A. Mauser, J. Swenson, and S. C. Kenney. 2000. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J. Virol. 74:1224-1233.
2. Adamson, A. L., and S. C. Kenney. 1998. Rescue of the Epstein-Barr virus BZLF1 mutant, Z (S186A), early gene activation defect by the BRLF1 gene product. Virology 251:187-197.
3. Bonnet, M., J. M. Guinebretiere, E. Kremmer, V. Grunewald, E. Benhamou, G. Contesso, and I. Joab. 1999. Detection of Epstein-Barr virus in invasive breast cancers. J. Natl. Cancer Inst. 91:1376-1381.
4. Busson, P., G. Ganem, P. Flores, F. Mugneret, B. Clausse, B. Caillou, K. Braham, H. Wakasugi, M. Lipinski, and T. Tursz. 1988. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int. J. Cancer 42:599-606.
5. Chang, Y., D. Dong, G. Hayward, and S. D. Hayward. 1990. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J. Virol. 64:3358-3369.
6. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV) encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an early EBV promoter. EMBO J. 5:3243-3249.
7. Cochet, C., D. Martel-Renoir, V. Grunewald, J. Bosq, G. Cochet, G. Schwaab, J. F. Bernaudin, and I. Joab. 1993. Expression of the Epstein-Barr virus immediate-early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 197:3358-3365.
8. Conners, T. A. 1995. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2:702-709.
9. Dmitriev, I., V. Krasnykh, C. R. Miller, M. Wang, E. Kashentseva, G. Mikheeva, N. Belousova, and D. T. Curiel. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72:9706-9713.
10. Feederle, R., M. Kost, M. Baumann, A. Janz, E. Drouet, W. Hammerschmidt, and H. J. Delecluse. 2000. The Epstein-Barr virus lytic program is controlled by the cooperative functions of two transactivators. EMBO J. 19:3080-3089.
11. Feighny, R. J., M. P. Farrell, and J. S. Pagano. 1980. Polypeptide synthesis and phosphorylation in Epstein-Barr virus-infected cells. J. Virol. 34:455-463.
12. Feighny, R. J., B. E. Henry II, and J. S. Pagano. 1981. Epstein-Barr virus-induced deoxynuclease and the reutilization of host-cell DNA degradation products in viral DNA replication. Virology 115:395-400.
13. Feng, W.-H., B. Israel, N. Raab-Traub, P. Busson, and S. C. Kenney. 2002. Chemotherapy induces lytic Epstein-Barr virus (EBV) replication and confers ganciclovir susceptibility to EBV-positive tumors. Cancer Res. 62:1920-1926.
14. Fixman, E., G. Hayward, and S. D. Hayward. 1992. trans-acting requirements for replication of Epstein-Barr virus ori-Lyt. J. Virol. 66:5030-5039.
15. Freeman, S. M., C. N. Abboud, K. A. Whartenby, C. H. Packman, D. S. Koeplin, D., F. L. Moolten, and G. N. Abraham. 1993. The "bystander" effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:5274-5283.
16. Gruffat, H., E. Manet, A. Rigolet, and A. Sergeant. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18:6835-6843.
17. Hamilton-Dutoit, S. J., D. Rea, M. Raphael, K. Sandvej, J. Deleclues, C. Gisselbrecht, L. Marelle, J. van Krieken, and G. Pallesen. 1993. Epstein-Barr virus latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Am. J. Pathol. 14:1072-1085.
18. Hammerschmidt, W., and B. Sugden. 1988. Identification and characterization of oriLyt, a lytic origin of replication of Epstein-Barr virus. Cell 55:427-433.
19. Harabuchi, Y., N. Yamanaka, A. Kataura, T. Kinoshita, F. Mizuno, and T. Osato. 1990. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal mid-line granuloma. Lancet 335:128-130.
20. Hardwick, J. M., S. Lazarowits, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
21. Henderson, S., D. Huen, M. Rowe, C. Dawson, G. Johnson, and A. B. Rickinson. 1993. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA 90:8479-8483.
22. Inman, G. J., U. K. Binne, G. A. Parker, P. J. Farrell, and M. J. Allday. 2001. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death . J. Virol. 75:2400-2410.
23. Israel, B. I., R. J. Pickles, D. M. Segal, R. D. Gerard, and S. C. Kenney. 2001. Enhancement of adenovirus vector entry into CD70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody. J. Virol. 75:5215-5221.
24. Kawanish, M. 1993. Epstein-Barr virus induces fragmentation of chromosomal DNA during lytic infection. J. Virol. 67:7654-7658.
25. Kenney, S., J.-Q. Ge, E. M. Westphal, and J. Olsen. 1998. Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors. Hum. Gene Ther. 9:1131-1141.
26. Kenney, S. C., J. Kamine, E. Holley-Guthrie, J.-C. Lin, E.-C. Mar, and J. Pagano. 1989. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63:1729-1736.
27. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2397. In B. Fields, D. Knipe, and P. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
28. Leon, R. P., T. Hedlund, S. J. Meech, S. Li, J. Schaack, S. P. Hunger, R. C. Duke, and J. DeGregori. 1998. Adenoviral-mediated gene transfer in lymphocytes. Proc. Natl. Acad. Sci. USA 95:13159-13164.
29. Le Roux, F., A. Sergeant, and L. Corbo. 1996. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome. J. Gen. Virol. 77:501-509.
30. Liebowitz, D. 1994. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin. Oncol. 21:376-381.
31. Litter, E., and J. Arrand. 1998. Characterization of the Epstein-Barr viruscoded thymidine kinase expressed in heterologous eucaryotic and prokaryotic systems. J. Virol. 62:3892-3895.
32. Loubiere, L., M. Tiraby, C. Cazaux, E. Brisson, M. Grisoni, J. C. Zhao-Emonet, G. Tiraby, and D. Klatzmann. 1999. The equine herpes virus 4 thymidine kinase is a better suicide gene than the human herpes virus 1 thymidine kinase. Gene Ther. 6:1638-1642.
33. MacMahon, E. M. E., J. D. Glass, S. D. Hayward, R. B. Mann, P. S. Becker, P. Charache, J. C. McArthur, and R. F. Ambinder. 1991. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969-973.
34. Magrath, I., V. Jain, and K. Bhatia. 1992. Epstein-Barr virus and Burkitt's lymphoma. Semin. Cancer Biol. 3:285-295.
35. Marshall, W. L., C. Yim, E. Gustafson, T. Graf, D. R. Sage, K. Hanify, L. Williams, J. Fingeroth, and R. W. Finberg. 1999. Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with Bax and Bak. J. Virol. 73:5181-5185.
36. McClain, K., C. Leach, H. Jenson, V. Joshi, B. Pollock, R. Parmley, F. DiCarlo, F. Chadwick, and S. Murphy. 1995. Association of Epstein-Barr virus with leiomyosarcoma in children with AIDS. N. Engl. J. Med. 332:12-18.
37. Moore, S. M., J. S. Cannon, Y. C. Tanhehco, F. M. Hamzeh, and R. F. Ambinder. 2001. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob. Agents Chemother. 45:2082-2091.
38. Raab-Traub, N. 1992. Epstein-Barr virus and nasopharyngeal carcinoma. Semin. Cancer Biol. 3:297-307.
39. Raab-Traub, N., and K. Flynn. 1986. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47:883-889.
40. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein disrupts latency in B lymphocytes. J. Virol. 72:7978-7984.
41. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. Fields, D. Knipe, and P. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
42. Rooney, C., D. Rowe, T. Ragot, and P. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus transactivates an early EBV promoter and induces the lytic productive cycle. J. Virol. 63:3109-3116.
43. Rooney, C., N. Taylor, J. Countryman, H. Jenson, J. Kolman, and G. Miller. 1988. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc. Natl. Acad. Sci. USA 85:9801-9805.
44. Shih-Lammali, F., F. Berger, P. Busson, and T. Ooka. 1996. Expression of the Dnase encoded by the BGLF5 gene of Epstein-Barr virus in nasopharyngeal carcinoma epithelial carcinoma cells. Virology 222:64-74.
45. Shibata, D., and L. Weiss. 1992. Epstein-Barr virus-associated gastric carcinoma. Am. J. Pathol. 140:769-774.
46. Sugawara, Y., M. Makuuchi, and K. Takada. 2000. Detection of Epstein-Barr virus DNA in hepatocellular carcinoma tissues from hepatitis C-positive patients. Scand. J. Gastroenterol. 35:981-984.
47. Sullivan, V., C. Talarico, S. Stanat, M. Davis, D. Coen, and K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
48. Swenson, J., A. Mauser, W. Kaufmann, and S. Kenney. 1999. The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J. Virol. 73:6540-6550.
49. Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. trans activation of the latent Epstein-Barr virus genome after transfection of the EBV DNA fragment. J. Virol. 57:1016-1022.
50. Takimoto, T., M. Kamide, and R. Umeda. 1984. Establishment of Epstein-Barr virus (EBV)-associated nuclear antigen (EBNA)-positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch. Oto-Rhino-Laryngol. 239:87-92.
51. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94:3352-3356.
52. Weiss, L., L. Movahed, R. Warnke, and J. Sklar. 1989. Detection of Epstein-Bar viral genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med. 320:502-506.
53. Westphal, E. M., W. Blachstock, W.-H. Feng, B. Israel, and S. C. Kenney. 2000. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 60:5781-5788.
54. Westphal, E. M., A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and S. Kenney. 1999. Induction of lytic Epstein-Barr virus (EBV) infection in EBV. associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res. 59:1485-1491.
55. Wildner, O., R. M. Blaese, and F. Candotti. 1999. Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res. 59:5233-5238.
56. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194-9199.
57. zur Hausen, H., H. Schulte-Holthausen, G. Klein, W. Henle, G. Henle, P., Clifford, and L. Santesson. 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056-1058.